Bion-1301 phase 3
WebAug 31, 2024 · BION-1301 offers them a second shot on goal with superior potency. Key readouts for both assets are approaching in 2024. ... Ongoing PROTECT phase 3 study met its interim primary endpoint at 49.8% ... WebPart 3 of Chinook's phase 1b study of BION-1301 is currently enrolling IgAN patients in an open-label setting, and Chinook expects to present a small subset of interim patient data in an oral presentation at the 58 th ERA-EDTA Congress in June, as well as additional patient data at the ASN Kidney Week 2024 in November. •
Bion-1301 phase 3
Did you know?
WebNov 4, 2024 · Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. WebDec 8, 2024 · A single-dose non-human primate study administering intravenous BION-1301 at 0.3, 3 and 30 mg/kg dose levels, yielded PK parameters typical for IgG4 class antibodies and absence of tolerability issues. ... Following identification of a recommended Phase 2 dose, an expanded cohort will investigate clinical activity of single-agent BION-1301. The ...
WebNov 4, 2024 · Data was presented from Cohort 1 in Part 3 of the ongoing phase 1/2 multi-center trial (see www.clinicaltrials.gov, identifier NCT03945318) evaluating the safety, … WebNov 4, 2024 · Updated data from Cohort 1 and initial data from Cohort 2 were presented from Part 3 of the ongoing phase 1/2 multi-center trial (see www.clinicaltrials.gov, identifier NCT03945318) evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical responses of open-label BION-1301 treatment in …
WebMar 31, 2024 · Part 3 of Chinook's phase 1b study of BION-1301 is currently enrolling IgAN patients in an open-label setting, and Chinook expects to present a small subset of interim patient data in an oral presentation at the 58 th ERA-EDTA Congress in June, as well as additional patient data at the ASN Kidney Week 2024 in November. Web1 day ago · The MarketWatch News Department was not involved in the creation of this content. SEATTLE, April 13, Apr 13, 2024 (GLOBE NEWSWIRE via COMTEX) -- SEATTLE, April 13, 2024 (GLOBE NEWSWIRE) -- Chinook ...
WebAug 23, 2024 · Similarly, BION-1301, another novel humanized anti-APRIL monoclonal antibody, has been developed as a potential treatment for patients with IgAN. The interim …
WebNov 14, 2024 · Once an RP2D is identified, Phase 2 of the study will open and continue to evaluate the safety and preliminary efficacy of BION-1301 administered at selected dose … cynthia crowley pillows new yorkWebDec 31, 2024 · Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular … cynthia crow van alstyneWebNov 4, 2024 · Data was presented from Cohort 1 in Part 3 of the ongoing phase 1/2 multi-center trial (see www.clinicaltrials.gov, identifier NCT03945318) evaluating the safety, … cynthia cruickshankWebNov 4, 2024 · These data reinforce our confidence in the dose and schedule we have selected to take forward in the phase 3 trial of BION-1301 for patients with IgAN that we plan to initiate next year.” cynthia croysdale roche obituaryWebApr 11, 2024 · Chinook Therapeutics Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Clinical Trial in Healthy Volunteers Published: April 11, 2024 at 8:00 a.m. ET cynthia cruickshank bioWebMay 19, 2024 · Chinook's lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular … cynthia crowecynthia cruickshank rivera